MEET OUR TEAM
Lynn Seely
CEO
Jarrad Aguirre
Head of Corporate Strategy and Advocacy
Simona Bank
Associate, Corporate Strategy
Juliette Fry
Advocacy Associate
Sheridan Matthews
Associate Director, Marketing
Suzy Obst
Head of Corporate Strategy
ABOUT US
Description
We are committed to addressing unmet need in women’s health and prostate cancer through purpose-driven science, empowering medicines, and transformative advocacy.
Our purpose is resolute and fueled by the opportunity to improve the lives of millions of patients, many impacted by diseases during their most productive years of life. Despite the significant burden of these diseases, patients do not have the options they deserve and need.
Our purpose is resolute and fueled by the opportunity to improve the lives of millions of patients, many impacted by diseases during their most productive years of life. Despite the significant burden of these diseases, patients do not have the options they deserve and need.
VIEW OUR USEFUL RESOURCES
VIEW OUR SESSION
Name
PANEL DISCUSSION: CEO Leadership Panel - Boardroom Talk Pharmaceutical Companies on Women’s Health
Date & Time
Tuesday, September 15, 2020, 8:00 AM - 9:00 AM
Speakers
Rachel Braun Scherl - Spark Solutions for Growth
Al Altomari - Agile Therapeutics
Sabrina Johnson - Dare Bioscience
David Portman - Sermonix Pharmaceuticals
Lynn Seely - Myovant Sciences
Angie Kalousek Ebrahimi - Blue Shield of California
Al Altomari - Agile Therapeutics
Sabrina Johnson - Dare Bioscience
David Portman - Sermonix Pharmaceuticals
Lynn Seely - Myovant Sciences
Angie Kalousek Ebrahimi - Blue Shield of California





Description
- What are the challenges for pharmaceutical players in embracing women’s health and how the eco-system can help solve those issues?
- Patient-centric is a matter of survival now: Behaviour outside of clinic -central to providers’ success
- How to ensure and advance access to information and treatments/therapies
- Long lasting and meaningful impact for women’s health via investments, divestments, spin offs and acquisitions. How these strategies impact innovation
- Lessons learned from Covid-19
Session Type
Panel
Virtual Session Link